IMS Launches Integrated Regulatory Compliance Solution for Pharmaceutical and Medical Device Companies
18 Février 2010 - 5:30PM
Business Wire
IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced the launch of IMS Aggregate Spend Compliance Services, a
comprehensive set of solutions to help pharmaceutical and medical
device companies comply with the growing number of federal and
state transparency and marketing disclosure laws in the U.S., known
as “aggregate spend” reporting regulations. IMS’s suite of
information and advisory services enables clients to implement a
fully integrated monitoring and reporting compliance infrastructure
– providing an accurate view of their promotional spend associated
with healthcare professionals. The services leverage the
best-in-class compliance application platform of R-Squared Services
& Solutions, a leading developer of evidence-based compliance
solutions for the healthcare and life sciences industries.
“Tracking and monitoring the total promotional spend to
healthcare providers is a difficult operational challenge that many
life sciences companies struggle with daily,” said Don Otterbein,
IMS general manager, Business Transformation Services. “IMS
Aggregate Spend Compliance Services enable our clients to align and
manage professional and organizational information across disparate
systems and functions – effectively addressing the complexities in
data capture, standardization and integration. Our solution also
includes a flexible and scalable reporting system, allowing for
quick response to evolving regulations and reporting
requirements.”
IMS Aggregate Spend Compliance Services bring together the
powerful capabilities of the IMS Business Transformation Services
organization, which leverages the company’s expertise in business
and compliance technology; IMS Healthcare Relational Services™,
which combines the company’s industry-leading reference data and
advisory services for an accurate view of healthcare professionals;
and R-Squared’s SpendTracker® software, a flexible, scalable
platform that can be augmented as regulations change – delivering
custom reports to satisfy companies’ internal policies.
Since 2006, more than 20 states have introduced legislation
requiring pharmaceutical and device manufacturers to disclose
various financial transactions or exchanges of financial value to
healthcare providers and affiliated healthcare organizations.
Similar legislation has been introduced at the federal level.
IMS Aggregate Spend Compliance Services are among the many
solutions delivered by IMS Business Transformation Services, which
help clients improve decision support, reduce costs and add greater
staffing flexibility to their operations via an array of
best-in-class implementation and outsourcing services.
About IMS
Operating in more than 100 countries, IMS Health is the world’s
leading provider of market intelligence to the pharmaceutical and
healthcare industries. With $2.2 billion in 2009 revenue and more
than 55 years of industry experience, IMS offers leading-edge
market intelligence products and services that are integral to
clients’ day-to-day operations, including product and
portfolio management capabilities; commercial
effectiveness innovations; managed care and consumer health
offerings; and consulting and services solutions that improve
productivity and the delivery of quality healthcare worldwide.
Additional information is available at
http://www.imshealth.com.
IMS Health (NYSE:RX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
IMS Health (NYSE:RX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Ims Health, Inc. (New York Stock Exchange): 0 recent articles
Plus d'articles sur IMS Health